Barbara N Lubash - Net Worth and Insider Trading

Barbara N Lubash Net Worth

The estimated net worth of Barbara N Lubash is at least $36 Million dollars as of 2024-06-05. Barbara N Lubash is the 10% Owner of Flexion Therapeutics Inc and owns about 3,921,092 shares of Flexion Therapeutics Inc (FLXN) stock worth over $36 Million. Details can be seen in Barbara N Lubash's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Barbara N Lubash has not made any transactions after 2016-06-08 and currently still holds the listed stock(s).

Transaction Summary of Barbara N Lubash

Barbara N Lubash Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Barbara N Lubash owns 9 companies in total, including Flexion Therapeutics Inc (FLXN) , Glaukos Corp (GKOS) , and PhaseRx Inc (PZRXQ) among others .

Click here to see the complete history of Barbara N Lubash’s form 4 insider trades.

Insider Ownership Summary of Barbara N Lubash

Ticker	Comapny	Transaction Date	Type of Owner
FLXN	Flexion Therapeutics Inc	2016-06-08	10 percent owner
GKOS	Glaukos Corp	2015-06-24	10 percent owner
PZRXQ	PhaseRx Inc	2016-05-23	10 percent owner
		2014-09-09	10 percent owner
		2014-11-18	10 percent owner
		2007-05-14	10 percent owner
		2006-05-09	10 percent owner
		2006-03-13	other: Former 10% Holder
		2014-11-18	10 percent owner

Barbara N Lubash Latest Holdings Summary

Barbara N Lubash currently owns a total of 1 stock. Barbara N Lubash owns 3,921,092 shares of Flexion Therapeutics Inc (FLXN) as of June 8, 2016, with a value of $36 Million.

Latest Holdings of Barbara N Lubash

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
FLXN	Flexion Therapeutics Inc	2016-06-08	3,921,092	9.12	35,760,359

Holding Weightings of Barbara N Lubash

Barbara N Lubash Form 4 Trading Tracker

According to the SEC Form 4 filings, Barbara N Lubash has made a total of 0 transactions in Flexion Therapeutics Inc (FLXN) over the past 5 years. The most-recent trade in Flexion Therapeutics Inc is the acquisition of 714,285 shares on June 8, 2016, which cost Barbara N Lubash around $10 Million.

Insider Trading History of Barbara N Lubash

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Barbara N Lubash Trading Performance

GuruFocus tracks the stock performance after each of Barbara N Lubash's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Barbara N Lubash is 20.21%. GuruFocus also compares Barbara N Lubash's trading performance to market benchmark return within the same time period. The performance of stocks bought by Barbara N Lubash within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Barbara N Lubash's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Barbara N Lubash

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	15.25
Relative Return to S&P 500(%)	14.74

Barbara N Lubash Ownership Network

Ownership Network List of Barbara N Lubash

No Data

Ownership Network Relation of Barbara N Lubash

Barbara N Lubash Owned Company Details

What does Flexion Therapeutics Inc do?

Who are the key executives at Flexion Therapeutics Inc?

Barbara N Lubash is the 10 percent owner of Flexion Therapeutics Inc. Other key executives at Flexion Therapeutics Inc include General Counsel Mark S. Levine , Chief Regulatory Officer Kerry Wentworth , and Chief Strategy Officer Christina Willwerth .

Flexion Therapeutics Inc (FLXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Flexion Therapeutics Inc (FLXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Flexion Therapeutics Inc (FLXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Flexion Therapeutics Inc (FLXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Flexion Therapeutics Inc Insider Transactions

No Available Data

What does Glaukos Corp do?

Who are the key executives at Glaukos Corp?

Barbara N Lubash is the 10 percent owner of Glaukos Corp. Other key executives at Glaukos Corp include SVP & Chief Financial Officer Alex R. Thurman , CFO & SVP Corporate Development Joseph E Gilliam , and director & 10 percent owner & Chief Executive Officer Thomas William Burns .

Glaukos Corp (GKOS) Insider Trades Summary

Over the past 18 months, Barbara N Lubash made no insider transaction in Glaukos Corp (GKOS). Other recent insider transactions involving Glaukos Corp (GKOS) include a net sale of 520,000 shares made by Thomas William Burns , a net sale of 299,404 shares made by Joseph E Gilliam , and a net sale of 6,762 shares made by Alex R. Thurman .

In summary, during the past 3 months, insiders sold 95,557 shares of Glaukos Corp (GKOS) in total and bought 0 shares, with a net sale of 95,557 shares. During the past 18 months, 895,823 shares of Glaukos Corp (GKOS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 895,823 shares.

Glaukos Corp (GKOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Glaukos Corp Insider Transactions

No Available Data

What does PhaseRx Inc do?

Who are the key executives at PhaseRx Inc?

Barbara N Lubash is the 10 percent owner of PhaseRx Inc. Other key executives at PhaseRx Inc include Chief Medical Officer Gordon Brandt , director & 10 percent owner Steven Gillis , and director & 10 percent owner Brian G Atwood .

PhaseRx Inc (PZRXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PhaseRx Inc (PZRXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhaseRx Inc (PZRXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PhaseRx Inc (PZRXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

PhaseRx Inc Insider Transactions

No Available Data

What does Inogen Inc do?

Who are the key executives at Inogen Inc?

Barbara N Lubash is the 10 percent owner of Inogen Inc. Other key executives at Inogen Inc include EVP & Gen. Counsel & Secretary Jason Somer , EVP & Chief Medical Officer Stanislav Glezer , and EVP & CFO and Treasurer Kristin A. Caltrider .

Inogen Inc (INGN) Insider Trades Summary

Over the past 18 months, Barbara N Lubash made no insider transaction in Inogen Inc (INGN). Other recent insider transactions involving Inogen Inc (INGN) include a net sale of 10,000 shares made by Jason Somer ,

In summary, during the past 3 months, insiders sold 10,000 shares of Inogen Inc (INGN) in total and bought 0 shares, with a net sale of 10,000 shares. During the past 18 months, 10,000 shares of Inogen Inc (INGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 10,000 shares.

Inogen Inc (INGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Inogen Inc Insider Transactions

No Available Data

What does Second Sight Medical Products Inc do?

Who are the key executives at Second Sight Medical Products Inc?

Barbara N Lubash is the 10 percent owner of Second Sight Medical Products Inc. Other key executives at Second Sight Medical Products Inc include Chief Medical Officer Lisa Ellen Porter , Chief Business Officer Donald Dwyer , and COO Truc Le .

Second Sight Medical Products Inc (EYES) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Second Sight Medical Products Inc (EYES) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Second Sight Medical Products Inc (EYES) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Second Sight Medical Products Inc (EYES)'s detailed insider trading history can be found in Insider Trading Tracker table.

Second Sight Medical Products Inc Insider Transactions

No Available Data

What does Insulet Corp do?

Who are the key executives at Insulet Corp?

Barbara N Lubash is the 10 percent owner of Insulet Corp. Other key executives at Insulet Corp include CCO Shacey Petrovic , SVP & Global Operations Prem Singh , and EVP & CFO Wayde D. Mcmillan .

Insulet Corp (PODD) Insider Trades Summary

Over the past 18 months, Barbara N Lubash made no insider transaction in Insulet Corp (PODD). Other recent insider transactions involving Insulet Corp (PODD) include a net sale of 76,609 shares made by Shacey Petrovic , a net sale of 31,401 shares made by Charles Alpuche , and a net sale of 2,643 shares made by Wayde D. Mcmillan .

In summary, during the past 3 months, insiders sold 3,300 shares of Insulet Corp (PODD) in total and bought 0 shares, with a net sale of 3,300 shares. During the past 18 months, 114,700 shares of Insulet Corp (PODD) were sold and 8,851 shares were bought by its insiders, resulting in a net sale of 105,849 shares.

Insulet Corp (PODD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Insulet Corp Insider Transactions

No Available Data

What does Paratek Pharmaceuticals Inc do?

Who are the key executives at Paratek Pharmaceuticals Inc?

Barbara N Lubash is the 10 percent owner of Paratek Pharmaceuticals Inc. Other key executives at Paratek Pharmaceuticals Inc include CLO & General Counsel & Sec. William M. Haskel , President & Chief Commercial Adam Woodrow , and Chief Development & Regulatory Randall B. Brenner .

Paratek Pharmaceuticals Inc (PRTK) Insider Trades Summary

Over the past 18 months, Barbara N Lubash made no insider transaction in Paratek Pharmaceuticals Inc (PRTK). Other recent insider transactions involving Paratek Pharmaceuticals Inc (PRTK) include a net sale of 172,206 shares made by Evan Loh , a net sale of 98,375 shares made by Michael Bigham , and a net sale of 79,527 shares made by William M. Haskel .

In summary, during the past 3 months, insiders sold 0 shares of Paratek Pharmaceuticals Inc (PRTK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 442,355 shares of Paratek Pharmaceuticals Inc (PRTK) were sold and 788,500 shares were bought by its insiders, resulting in a net purchase of 346,145 shares.

Paratek Pharmaceuticals Inc (PRTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Paratek Pharmaceuticals Inc Insider Transactions

No Available Data

What does Alexza Pharmaceuticals Inc do?

Who are the key executives at Alexza Pharmaceuticals Inc?

Barbara N Lubash is the other: Former 10% Holder of Alexza Pharmaceuticals Inc. Other key executives at Alexza Pharmaceuticals Inc include director & President & CEO Thomas Braxton King , Former SVP & CFO & Secretary Mark K Oki , and EVP & Operations & COO Robert A Lippe .

Alexza Pharmaceuticals Inc (ALXA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alexza Pharmaceuticals Inc (ALXA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alexza Pharmaceuticals Inc (ALXA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alexza Pharmaceuticals Inc (ALXA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alexza Pharmaceuticals Inc Insider Transactions

No Available Data

What does Vivani Medical Inc do?

Who are the key executives at Vivani Medical Inc?

Barbara N Lubash is the 10 percent owner of Vivani Medical Inc. Other key executives at Vivani Medical Inc include director & 10 percent owner Gregg Williams , CFO Brigid Makes , and Chief Business Officer Donald Dwyer .

Vivani Medical Inc (VANI) Insider Trades Summary

Over the past 18 months, Barbara N Lubash made no insider transaction in Vivani Medical Inc (VANI). Other recent insider transactions involving Vivani Medical Inc (VANI) include a net purchase of 2,768,102 shares made by Gregg Williams , a net purchase of 26,500 shares made by Donald Dwyer , and a net purchase of 119,000 shares made by Joachim Eberhard Bolck .

In summary, during the past 3 months, insiders sold 0 shares of Vivani Medical Inc (VANI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vivani Medical Inc (VANI) were sold and 2,938,602 shares were bought by its insiders, resulting in a net purchase of 2,938,602 shares.

Vivani Medical Inc (VANI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vivani Medical Inc Insider Transactions

No Available Data

Barbara N Lubash Mailing Address

Above is the net worth, insider trading, and ownership report for Barbara N Lubash. You might contact Barbara N Lubash via mailing address: One Sansome Street, Suite 3630, San Francisco Ca 94104.

Discussions on Barbara N Lubash

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.